THE BROAD INSTITUTE, INC.;BAYER AKTIENGESELLSCHAFT;BAYER PHARMA AKTIENGESELLSCHAFT;DANA-FARBER CANCER INSTITUTE, INC.
发明人:
TIMOTHY A. LEWIS,XIAOYUN WU,HEIDI GREULICH,MATTHEW MEYERSON,MANUEL ELLERMANN,PHILIP LIENAU,KNUT EIS,ANTJE MARGRET WENGNER,CHARLOTTE CHRISTINE KOPITZ,MARTIN LANGE
申请号：
US16480498
公开号：
US20200062741A1
申请日:
2018.02.01
申请国别(地区):
US
年份:
2020
代理人:
摘要：
The present invention features improved compounds, especially the compound having the structure (1). Compositions and methods of identifying patients having cancer using biomarkers (e.g., PDE3A, PDE3B, SLFN12 and/or CREB3L1) that correlate with drug sensitivity and consequently treating a stratified patient population with an agent of the invention.
